Metabolism and pharmacokinetic studies of JPH203, an L-Amino acid transporter 1 (LAT1) selective compound

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 1, 2012, Pages 155-161

  Wempe, Michael F ^a   Rice, Peter J ^a,b   Lightner, Janet W ^b   Jutabha, Promsuk ^c   Hayashi, Michinari ^c   Anzai, Naohiko ^c,d   Wakui, Shin ^e   Kusuhara, Hiroyuki ^f   Sugiyama, Yuichi ^f   Endou, Hitoshi ^c,g  

^a UNIVERSITY OF COLORADO   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e AZABU UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g J Pharma Co   (Japan)

Author keywords

Bio analytical pharmacokinetic (BAPK); In vitro and in vivo metabolism; JPH203 (KYT 0353); L Amino acid transporter (LAT); Liquid chromatography mass spectrometrymass spectrometry (LC MS MS)

Indexed keywords

AMINO ACID TRANSPORTER; ANTINEOPLASTIC AGENT; JPH 203; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIQUID CHROMATOGRAPHY; LIVER; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NAT GENE; NONHUMAN; RAT; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TOXICITY TESTING;

EID: 84857750592     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-091     Document Type: Article

References (16)

1. Christensen, H. N.: Role of amino acid transport and counter transport in nutrition and metabolism. Physiol. Rev., 70: 43-77 (1990).
2. Kanai, Y., Segawa, H., Miyamoto, K., Uchino, H., Takeda, E. and Endou, H.: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem., 273: 23629-23632 (1998).
3. Segawa, H., Fukasawa, Y., Miyamoto, K., Takeda, E., Endou, H. and Kanai, Y.: Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J. Biol. Chem., 274: 19745-19751 (1999).
4. Babu, E., Kanai, Y., Chairoungdua, A., Kim, D. K., Iribe, Y., Tangtrongsup, S., Jutabha, P., Li, Y., Ahmend, N., Sakamoto, S., Anzai, N., Nagamori, S. and Endou, H.: Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J. Biol. Chem., 278: 43838-43845 (2003).
5. Bodoy, S., Martin, L., Zorzano, A., Palacin, M., Estevez, R. and Bertran, J.: Identification of LAT4, a novel amino acid transporter with system L activity. J. Biol. Chem., 280: 12002-12011 (2005).
6. Yanagida, O., Kanai, Y., Chairoungdua, A., Kim, D. K., Segawa, H., Nii, T., Cha, S. H., Matsuo, H., Fukushima, J., Fukasawa, Y., Tani, Y., Taketani, Y., Uchino, H., Kim, J. Y., Inatomi, J., Okayasu, I., Miyamoto, K., Takeda, E., Goya, T. and Endou, H.: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta, 1514: 291-302 (2001).
7. Uchino, H., Kanai, Y., Kim, D. K., Wempe, M. F., Chairoungdua, A., Morimoto, E., Anders, M. W. and Endou, H.: Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol., 61: 729-737 (2002).
8. Morimoto, E., Kanai, Y., Kim, D. K., Chairoungdua, A., Choi, H. W., Wempe, M. F., Anzai, N. and Endou, H.: Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. J. Pharmacol. Sci., 108: 505-516 (2008).
9. Oda, K., Hosoda, N., Endo, H., Saito, K., Tsujihara, K., Yamamura, M., Sakata, T., Anzai, N., Wempe, M. F., Kanai, Y. and Endou, H.: L-type Amino Acid Transporter 1 Inhibitors Inhibit Tumor Cell Growth. Cancer Sci., 101: 173-179 (2010).
10. Little, J. L., Wempe, M. F. and Buchanan, C. M.: Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: Examining lipid matrix ionization effects in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 833: 219-230 (2006).
11. Obach, R. S.: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 27: 1350-1359 (1999).
12. Levy, R. H., Thummel, K. E., Trager, W. F., Hansten, P. D. and Eichelbaum, M.: Metabolic Drug Interactions. Philadelphia, PA, Lippincott Williams & Wilkins, 2000.
13. Trepanier, L. A., Ray, K., Winand, N., Spielberg, S. P. and Cribb, A. E.: Cytosolic Arylamine N-Acetyltransferase (NAT) Deficiency in the Dog and Other Canids Due to an Absence of NAT Genes. Biochem. Pharmacol., 54: 73-80 (1997).
14. Hein, D. W., McQueen, C. A., Grant, D. M., Goodfellow, G. H., Kadlubar, F. F. and Weber, W. W.: Pharmacogenetics of the Arylamine N-Acetyltransferases: A Symposium in Honor of Wendell W. Weber. Drug Metab. Dispos., 28: 1425-1432 (2000).
15. Butcher, N. J., Boukouvala, S., Sim, E. and Minchin, R. F.: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J., 2: 30-42 (2002).
16. Wempe, M. F., Wright, C., Little, J. L., Lightner, J. W., Large, S. E., Caflisch, G. B., Buchanan, C. M., Rice, P. J., Wacher, V. J., Ruble, K. M. and Edgar, K. J.: Inhibiting efflux with novel nonionic surfactants: Rational design based on vitamin E TPGS. Int. J. Pharm., 370: 93-102 (2009).